BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA).Related Links: UK Clears Gilead's Remdesivir For Some Coronavirus Patients Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir Latest Ratings for BMRN View More Analyst Ratings for BMRN  View the Latest Analyst Ratings See more from Benzinga